MENLO PARK, Calif., March 19, 2026 /PRNewswire/ -- Endovascular Engineering, Inc. ("E2") today announced that two abstracts related to the ENGULF study and the Hēlo® Platform have been accepted as ...
These presentations build upon momentum from E2's late-breaking presentation at VIVA 2025 in Las Vegas, which introduced initial ENGULF pivotal cohort outcomes. Each presentation showcases distinct, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results